A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors

Trial Profile

A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs BMS 986156 (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 18 Jul 2017 Planned End Date changed from 24 May 2018 to 1 Feb 2019.
    • 18 Jul 2017 Planned primary completion date changed from 23 May 2018 to 30 Jan 2019.
    • 06 Jun 2017 Preliminary dose escalation results (n=66 as of 12 Dec 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top